Revenues and other income (Tables)

6 Months Ended

Jun. 30, 2019

Revenues and other income

Schedule of revenues

	Six months ended June 30,
	2019		2018
	(Euro, in thousands)
Recognition of non-refundable upfront payments and license fees	€	42,113	€	52,753
Gilead collaboration agreement for filgotinib		41,069		49,331
AbbVie collaboration agreement for CF		1,044		3,422
Milestone payments		33,383		28,567
Gilead collaboration agreement for filgotinib		10,034		16,023
AbbVie collaboration agreement for CF		23,349		12,544
Reimbursement income		11,344		558
Novartis collaboration agreement for MOR106		10,595		—
AbbVie collaboration agreement for CF		749		558
Other revenues		4,944		5,705
Fee-for-services revenues		4,878		5,641
Other		66		64
Total revenues	€	91,785	€	87,583